阿达木单抗治疗葡萄膜炎患者的长期随访:应答率及停药原因
荷兰鹿特丹两家三级眼科中心的回顾性队列研究纳入341例非感染性葡萄膜炎患者(633只患眼),评估阿达木单抗的真实世界有效性和停药原因;178例在继续用药期间达到疾病不活动,51例停药后维持缓解,115例中40例(35%)检出阿达木单抗抗体,抗体与较低药物水平相关且在单药治疗者中更常见(P < .01)。
要点
- 341例非感染性葡萄膜炎患者中178例在继续阿达木单抗治疗期间达到疾病不活动,51例停药后维持缓解。
- 115例检测者中40例(35%)检出阿达木单抗抗体,抗体与较低阿达木单抗水平相关。
- 抗体在阿达木单抗单药治疗患者中更常见(P < .01)。
核心结论
- 阿达木单抗对非感染性葡萄膜炎有效,副作用谱可接受;尽管可能复发,多数患者停用阿达木单抗后达到疾病不活动或缓解,且未使用其他全身免疫抑制药物。
研究设计与样本
- 回顾性临床队列研究,对荷兰鹿特丹2家三级眼科中心的临床实践进行病历回顾,数据收集自2004年5月1日至2020年9月1日,纳入接受阿达木单抗治疗的非感染性葡萄膜炎患者341例(633只患眼)。
主要发现
- 葡萄膜炎无复发生存间期为3.4年(范围0-13年)。
- 178例患者在继续阿达木单抗治疗期间达到疾病不活动,51例患者在停用阿达木单抗后维持缓解。
- 停药原因包括无应答、复发或与治疗有效性无关的原因。
- 115例检测患者中40例(35%)存在阿达木单抗抗体,抗体与较低阿达木单抗水平相关。
- 抗体在阿达木单抗单药治疗患者中更常见(P < .01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effectiveness and reasons for discontinuation including the side effect profiles of adalimumab in a real-world setting. DESIGN: Retrospective clinical cohort study. METHODS: A medical chart review of clinical practice in 2 tertiary eye care services in Rotterdam, the Netherlands, was performed Data were collected from May 1, 2004, through September 1, 2020. Patients with noninfectious uveitis treated with adalimumab (n = 341; 633 affected eyes) were included. The primary outcome was the effectiveness of adalimumab, measured by the number of patients achieving inactive disease, remission, and relapse-free survival. The secondary outcomes were the reasons for discontinuation, including side effects, and the number of patients who developed antibodies. RESULTS: In total, 341 patients were treated with adalimumab between May 2004 and September 2020. The uveitis recurrence-free survival interval was 3.4 years (range, 0-13 years). Adalimumab had an acceptable side effect profile. A total of 178 patients achieved inactive disease while continuing adalimumab, and 51 patients maintained remission after discontinuing adalimumab. Reasons for discontinuation of adalimumab were no response, relapse, or reasons unrelated to the effectiveness of treatment. Adalimumab antibodies were present in 40 of 115 patients (35%). Antibodies were associated with lower adalimumab levels, and antibodies were observed more often in patients on adalimumab monotherapy (P < .01). CONCLUSIONS: Adalimumab is effective for patients with noninfectious uveitis, with an acceptable side effect profile. Although relapses can occur, the majority of the patients achieved inactive disease or remission after cessation of adalimumab, without other systemic immunosuppressive medication.
引用
- Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy. Am J Ophthalmol. 2022. PMID: 35314190. doi:10.1016/j.ajo.2022.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。